A network meta-analysis of the risk of immune-related renal toxicity in cancer patients treated with immune checkpoint inhibitors

Papers of special note have been highlighted as: • of interest

References

• 1 Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat. Med. 10(9), 909–915 (2004).
  Medline CASGoogle Scholar
• 2 Momtaz P, Postow MA. Immunologic checkpoints in cancer therapy: focus on the programmed death-1 (PD-1) receptor pathway. Pharmgenomics Pers. Med. 7, 357 (2014).
  Medline CASGoogle Scholar
• 3 Hodi FS, O'day SJ, Mcdermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363(8), 711–723 (2010).
  Medline CASGoogle Scholar
• 4 Robert C, Thomas L, Bondarenko I et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 364(26), 2517–2526 (2011).
  Medline CASGoogle Scholar
• 5 Hamid O, Robert C, Daud A et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N. Engl. J. Med. 369(2), 134–144 (2013).
  Medline CASGoogle Scholar
• 6 Robert C, Schachter J, Long GV et al. Pembrolizumab versus ipilimumab in advanced melanoma. N. Engl. J. Med. 372(26), 2521–2532 (2015).
  Medline CASGoogle Scholar
• 7 Garon EB, Rizvi NA, Hui R et al. Pembrolizumab for the treatment of non–small-cell lung cancer. N. Engl. J. Med. 372(21), 2018–2028 (2015).
  MedlineGoogle Scholar
• 8 Berger R, Rotem-Yehudar R, Slama G et al. Phase I safety and pharmacokinetic study of ct-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin. Cancer Res. 14(10), 3044–3051 (2008).
  Medline CASGoogle Scholar
• 9 Armand P, Nagler A, Weller EA et al. Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international Phase II trial. J. Clin. Oncol. 31(33), 4199–4206 (2013).
  Medline CASGoogle Scholar
• 10 Spira A, Park K, Mazieres J, Vansteenkiste J, Rittmeyer A, Ballinger M. Efficacy, safety and predictive biomarker results from a randomized phase II study comparing atezolizumab (MPDL3280A) vs docetaxel in 2L/3L NSCLC (POPLAR). J. Clin. Oncol. 33 (2015).
  Google Scholar
• 11 Brahmer JR, Tykodi SS, Chow LQ et al. Safety and activity of anti-PD-l1 antibody in patients with advanced cancer. N. Engl. J. Med. 366(26), 2455–2465 (2012).
  Medline CASGoogle Scholar
• 12 Abdel-Rahman O, Elhalawani H, Fouad M. Risk of cutaneous toxicities in patients with solid tumors treated with immune checkpoint inhibitors: a meta-analysis. Future Oncol. 11(17), 2471–2484 (2015).
  CASGoogle Scholar
• 13 Abdel-Rahman O, Elhalawani H, Fouad M. Risk of elevated transaminases in cancer patients treated with immune checkpoint inhibitors: a meta-analysis. Expert Opin. Drug Saf. 14(10), 1507–1518 (2015).
  Medline CASGoogle Scholar
• 14 Abdel-Rahman O, El Halawani H, Fouad M. Risk of endocrine complications in cancer patients treated with immune check point inhibitors; a meta-analysis. Future Oncol. (2015).
  Google Scholar
• 15 Abdel-Rahman O, ElHalawani H, Fouad M. Risk of gastrointestinal complications in cancer patients treated with immune checkpoint inhibitors; a meta-analysis. Immunotherapy 7(11), 1213–1227 (2015).
  CASGoogle Scholar
• 16 Westin JR, Chu F, Zhang M et al. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, Phase 2 trial. Lancet Oncol. 15(1), 69–77 (2014).
  Medline CASGoogle Scholar
• 17 Corsello SM, Barnabei A, Marchetti P, De Vecchis L, Salvatori R, Torino F. Endocrine side effects induced by immune checkpoint inhibitors. J. Clin. Endocrinol. Metab. 98(4), 1361–1375 (2013).
  Medline CASGoogle Scholar
• 18 Torino F, Barnabei A, Paragliola RM, Marchetti P, Salvatori R, Corsello SM. Endocrine side-effects of anti-cancer drugs: mAbs and pituitary dysfunction: clinical evidence and pathogenic hypotheses. Eur. J. Endocrinol. 169(6), R153–R164 (2013).
  Medline CASGoogle Scholar
• 19 Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the prisma statement. Ann. Intern. Med. 151(4), 264–269 (2009).
  MedlineGoogle Scholar
• 20 Jadad AR, Moore RA, Carroll D et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control. Clin. Trials 17(1), 1–12 (1996).
  Medline CASGoogle Scholar
• 21 Caldwell DM, Ades A, Higgins J. Simultaneous comparison of multiple treatments: combining direct and indirect evidence. Br. Med. J. 331(7521), 897 (2005).
  MedlineGoogle Scholar
• 22 Lu G, Ades A. Combination of direct and indirect evidence in mixed treatment comparisons. Stat. Med. 23(20), 3105–3124 (2004).
  Medline CASGoogle Scholar
• 23 Brahmer J, Reckamp KL, Baas P et al. Nivolumab versus docetaxel in advanced squamous cell non-small-cell lung cancer. N. Engl. J. Med. (2015).
  Google Scholar
• 24 Robert C, Long GV, Brady B et al. Nivolumab in previously untreated melanoma without braf mutation. N. Engl. J. Med. 372(4), 320–330 (2015).
  Medline CASGoogle Scholar
• 25 Weber JS, D'angelo SP, Minor D et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (checkmate 037): a randomised, controlled, open-label, Phase 3 trial. Lancet Oncol. 16(4), 375–384 (2015). • In this study, all grade renal toxicities happen in two patients (0.7%) in the nivolumab arm versus no patients in the chemotherapy arm.
  Medline CASGoogle Scholar
• 26 Borghaei H, Paz-Ares L, Horn L et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N. Engl. J. Med. 373(17), 1627–1639 (2015).
  Medline CASGoogle Scholar
• 27 Ribas A, Puzanov I, Dummer R et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (keynote-002): a randomised, controlled, Phase 2 trial. Lancet Oncol. 16(8), 908–918 (2015).
  Medline CASGoogle Scholar
• 28 Postow MA, Chesney J, Pavlick AC et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N. Engl. J. Med. 372(21), 2006–2017 (2015).
  MedlineGoogle Scholar
• 29 Larkin J, Chiarion-Sileni V, Gonzalez R et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 373(1), 23–34 (2015).
  Medline CASGoogle Scholar
• 30 Abdel-Rahman O. Immune checkpoints aberrations and gastric cancer; assessment of prognostic value and evaluation of therapeutic potentials. Crit. Rev. Oncol. Hematol. (2015).
  Google Scholar
• 31 Intlekofer AM, Thompson CB. At the bench: preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy. J. Leukoc. Biol. 94(1), 25–39 (2013).
  Medline CASGoogle Scholar
• 32 Alegre M-L, Noel PJ, Eisfelder BJ et al. Regulation of surface and intracellular expression of CTLA4 on mouse T cells. J. Immunol. 157(11), 4762–4770 (1996).
  Medline CASGoogle Scholar
• 33 Topalian SL, Hodi FS, Brahmer JR et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366(26), 2443–2454 (2012).
  Medline CASGoogle Scholar
• 34 Izzedine H, Gueutin V, Gharbi C et al. Kidney injuries related to ipilimumab. Invest. New Drugs 32(4), 769–773 (2014).
  Medline CASGoogle Scholar
• 35 Fadel F, Karoui KE, Knebelmann B. Anti-ctla4 antibody-induced lupus nephritis. N. Engl. J. Med. 361(2), 211–212 (2009).
  Medline CASGoogle Scholar
• 36 Abdel-Rahman O, Elhalawani H. Proteinuria in patients with solid tumors treated with ramucirumab: a systematic review and meta-analysis. Chemotherapy 60(5–6), 325–333 (2014).
  Medline CASGoogle Scholar
• 37 Weber JS, Kähler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J. Clin. Oncol. 30(21), 2691–2697 (2012).
  Medline CASGoogle Scholar
• 38 Thajudeen B, Madhrira M, Bracamonte E, Cranmer LD. Ipilimumab granulomatous interstitial nephritis. Am. J. Ther. 22(3), e84–e87 (2015).
  MedlineGoogle Scholar
• 39 Motzer RJ, Escudier B, Mcdermott DF et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N. Engl. J. Med. 373(19), 1803–1813 (2015).
  Medline CASGoogle Scholar
• 40 Bronstein Y, Ng CS, Hwu P, Hwu W-J. Radiologic manifestations of immune-related adverse events in patients with metastatic melanoma undergoing anti–CTLA-4 antibody therapy. AJR Am. J. Roentgenol. 197(6), W992–W1000 (2011).
  MedlineGoogle Scholar